Medical DevicesStrong organic growth in parts of the Medical Devices division is being offset by a normalization of dental volumes, limiting the division's overall revenue contribution.
Portfolio RestructuringDeliberate phase‑out of parts of the industrial portfolio is reducing revenue from industrial activities and could weigh on total revenue as the company repositions.
Sales ExecutionSales slightly below expectations due to unfavorable dynamics in certain commercial agreements could pressure revenue growth and investor sentiment.